Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial


Tannock I. F. , Fizazi K., Ivanov S., Karlsson C. T. , Flechon A., Skoneczna I., ...Daha Fazla

LANCET ONCOLOGY, cilt.14, sa.8, ss.760-768, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Konu: 8
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1016/s1470-2045(13)70184-0
  • Dergi Adı: LANCET ONCOLOGY
  • Sayfa Sayıları: ss.760-768

Özet

Background Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.